Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma

Predictive factors for response to regorafenib in recurrent glioblastoma, IDH-wildtype, are scarcely recognized. The objective of this study was to identify molecular predictive factors for response to regorafenib using a clinically available platform. We analyzed a prospective cohort of 30 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiesa, Silvia, Mangraviti, Antonella, Martini, Maurizio, Cenci, Tonia, Mazzarella, Ciro, Gaudino, Simona, Bracci, Serena, Martino, Antonella, Della Pepa, Giuseppe M., Offi, Martina, Gessi, Marco, Russo, Rosellina, Martucci, Matia, Beghella Bartoli, Francesco, Larocca, Luigi M., Lauretti, Liverana, Olivi, Alessandro, Pallini, Roberto, Balducci, Mario, D’Alessandris, Quintino Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519741/
https://www.ncbi.nlm.nih.gov/pubmed/36171338
http://dx.doi.org/10.1038/s41598-022-20417-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519741/
https://www.ncbi.nlm.nih.gov/pubmed/36171338
http://dx.doi.org/10.1038/s41598-022-20417-y

Ejemplares similares